Press "Enter" to skip to content

Timothy Church.

Weissfeld, M.D., M.P.H., Lance A. Yokochi, M.D., M.P.H., Timothy Church, Ph.D., Adeyinka O. Laiyemo, M.D., M.P.H., Robert Bresalier, M.D., Gerald L. Andriole, M.D., Saundra S. Buys, M.D., E. David Crawford, M.D., Mona N. Fouad, M.D., Claudine Isaacs, M.D., Christine C. Johnson, M.D., Ph.D., M.P.H., Douglas J. Reding, M.D., M.P.H., Barbara O’Brien, M.P.H., Danielle M. Carrick, Ph.D., Patrick Wright, B.S., Thomas L. Riley, B.S., Mark P. Purdue, Ph.D., Grant Izmirlian, Ph.D., Barnett S. Kramer, M.D., M.P.H., Anthony B. Miller, M.D., John K. Gohagan, Ph.D., Philip C. Prorok, Ph.D., and Christine D. Berg, M.D.Achieving statistical significance on essential endpoints, even with the tiny interim sample size evaluated, is compelling, stated Dr. Stephen Sonis. Davis, CEO and President of Access Pharmaceuticals. The clinical advantage is evident in the ever increasing commercial adoption of MuGard as evidenced by raising script volume, increasing reimbursement and inclusion in formularies of the biggest pharmacy benefit managers, insurance plans, group purchasing businesses, and leading cancer organizations such as Memorial Sloan Kettering Cancer Center here in NY. Access Pharmaceuticals intends on presenting final data, and getting the data published in peer examined publications, in 2012..